There are inadequate numbers of cancer clinical investigators to translate basic science advances into patient care. One reason for this shortage is inadequate clinical investigator training. Johns Hopkins is poised to address this deficiency. In July of 1992 we inaugurated a training program for clinical investigators through the Schools of Medicine and Hygiene. The Oncology Center was a leader in the development of this program. As a Comprehensive Cancer Center, there are abundant opportunities for clinical research in established programs at the lab/clinic interface. These programs have a record of training successful clinical investigators. This application describes that we will train oncologists to translate basic science advances into improved cancer prevention, detection, diagnosis, and treatment. Ross C. Donehower, M.D. will serve as the Director of this Program. There has been and will continue to be an Advisory Committee representing medical, surgical, radiation, and pediatric oncology disciplines. Faculty are established investigators in research programs at the lab/clinic interface. The core of the program will be to train clinical investigators in clinical investigation with mentored clinical research and results in a Master's or Ph.D. Degree. Trainees will have electives involving both cancer basic science and clinical trials and will perform clinical research at the lab/clinic interface. This application will ensure the Oncology Center's continuation as a major participant in the Hopkins Program. Trainee candidates from medical, pediatric, radiation, and surgical oncology fellowships or residencies will be selected on a rotating basis to assure that the program is available to all subspecialties. It continues to be our goal and vision that 5 fellows will be supported annually by this mechanism. Other support will be sought for additional trainees. Special efforts will be made to recruit minority candidates. Evaluation of the program will be executed regularly with participation of the Advisory Committee and former/active participants.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lei, Ming
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Mathieu, L N; Kanarek, N F; Tsai, H-L et al. (2014) Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008). Dis Esophagus 27:757-63
Brewster, A M; Jorgensen, T J; Ruczinski, I et al. (2006) Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer. Breast Cancer Res Treat 95:73-80
Strouse, John J; Cox, Christiane S; Melhem, Elias R et al. (2006) Inverse correlation between cerebral blood flow measured by continuous arterial spin-labeling (CASL) MRI and neurocognitive function in children with sickle cell anemia (SCA). Blood 108:379-81
Strouse, John J; Fears, Thomas R; Tucker, Margaret A et al. (2005) Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 23:4735-41
Brewster, Abenaa M; Alberg, Anthony J; Strickland, Paul T et al. (2004) XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 13:1271-5
Jacobsohn, David A; Vogelsang, Georgia B (2002) Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 62:879-89
Friedmann, Alison M; Sengul, Haydar; Lehmann, Harold et al. (2002) Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 16:34-45
Gillison, M L; Koch, W M; Capone, R B et al. (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-20
Dees, E C; O'Reilly, S; Goodman, S N et al. (2000) A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 18:521-9
Carey, L A; Kim, N W; Goodman, S et al. (1999) Telomerase activity and prognosis in primary breast cancers. J Clin Oncol 17:3075-81

Showing the most recent 10 out of 16 publications